# TREAT ctDNA (NCT05512364)

> Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05512364
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
- Conditions: ER-positive Breast Cancer; HER2-negative Breast Cancer; Stage IIB Breast Cancer; Stage III Breast Cancer
- Interventions: Elacestrant; Tamoxifen; Letrozole 2.5mg; Anastrozole 1mg; Exemestane 25 MG
- Enrollment: 220
- Primary outcome: Distant metastasis free survival (DMFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 14
- YouTube: 10
- X threads: 2
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=treat-ctdna-nct05512364

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05512364", "email": "<work email>"}; the inbox owner confirms by the emailed link.